The kinetic profile of clinical and laboratory findings and treatment outcome of patients with toxocariasis.
IgE
IgG
Vietnam
eosinophil
thiabendazole
toxocariasis
Journal
Tropical medicine & international health : TM & IH
ISSN: 1365-3156
Titre abrégé: Trop Med Int Health
Pays: England
ID NLM: 9610576
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
pubmed:
10
8
2021
medline:
1
1
2022
entrez:
9
8
2021
Statut:
ppublish
Résumé
Human toxocariasis is a widespread zoonosis for which a chemotherapy decision and therapy effectiveness are difficult to determine. We aimed to investigate the kinetic profile of clinical and laboratory findings and treatment outcome of patients with toxocariasis in Vietnam. The prospective study was conducted between October 2017 and June 2019. The diagnosis of toxocariasis was established based on clinical, laboratory (eosinophilia, raised IgE concentration) and serological (positive Toxocara IgG ELISA) evaluation as well as the exclusion of another helminthic co-infection. The patients were followed up after seven days, then one, three and six months after chemotherapy by thiabendazole. The study involved 80 patients with a mean age of 41.6 ± 15.2 years of whom 58.8% were female. At three and six months after chemotherapy, most patients demonstrated resolution of clinical signs and symptoms, eosinophil count and IgE concentration but not in the proportion of IgG seropositivity. Skin lesions and eosinophilia resolved earlier than the other symptoms (one month after treatment). About four-fifths of the patients were "cured" after three and six months of follow-up; 33.8% showed side effects to thiabendazole therapy but no severe events were reported. The most common adverse reaction was neurologic symptoms followed by gastrointestinal or skin manifestations which lasted as long as 4 days. In toxocariasis patients, cutaneous manifestations and eosinophilia resolve more rapidly than other clinical and laboratory findings while IgG titre has a very slow kinetic after therapy. Thiabendazole seems to be a potential alternative for the treatment of human toxocariasis.
Substances chimiques
Anthelmintics
0
Antibodies, Helminth
0
Thiabendazole
N1Q45E87DT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1419-1426Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Macpherson C. The epidemiology and public health importance of toxocariasis: a zoonosis of global importance. Int J Parasitol. 2013;43(12-13):999-1008.
Ma G, Holland CV, Wang T, Hofmann A, Fan C-K, Maizels RM, et al. Human toxocariasis. Lancet Infect Dis. 2018;18(1):e14-24.
Othman AA. Therapeutic battle against larval toxocariasis: are we still far behind? Acta Trop. 2012;124(3):171-8.
Caumes E. Treatment of cutaneous larva migrans and Toxocara infection. Fundam Clin Pharmacol. 2003;17(2):213-6.
Hombu A, Yoshida A, Kikuchi T, Nagayasu E, Kuroki M, Maruyama H. Treatment of larva migrans syndrome with long-term administration of albendazole. J Microbiol Immunol Infect. 2019;52(1):100-5.
Yoshikawa M, Koyama N, Hontsu S, Yamamoto Y, Ogawa S, Nakamura T, et al. [Clinical analysis of eight patients with pulmonary toxocariasis] [Article in Japanese]. Nihon Kokyuki Gakkai Zasshi. 2010;48(5):351-6.
Yoshikawa M, Koyama N, Hontsu S, Yamamoto Y, Mikasa K, Kimura H. Lessons from eight cases of adult pulmonary toxocariasis: abridged republication. Respirology. 2011;16(6):1014-5.
Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol. 2001;75(4):299-305.
Magnaval J. Apparent weak efficacy of ivermectin for treatment of human toxocariasis. Antimicrob Agents Chemother. 1998;42(10):2770.
McCarthy JS, Moore TA. Drugs for helminths. In: Mandell GL, Bennett JE, Dolin R (eds). Mandell, douglas, and bennett’s principles and practice of infectious diseases. 8th ed. Livingstone, Philadelphia, PA: Elsevier Churchill; 2015:519-527.
Stürchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol. 1989;83(5):473-8.
Magnaval J, Charlet J. Efficacité comparée du thiabendazole et du mébendazole dans le traitement de la toxocarose [Comparative efficacy of thiabendazole and mebendazole in the treatment of toxocariasis] [Article in French]. Therapie. 1987;42(6):541-4.
Wiśniewska-Ligier M, Woźniakowska-Gęsicka T, Sobolewska-Dryjańska J, Markiewicz-Jóźwiak A, Wieczorek M. Analysis of the course and treatment of toxocariasis in children - a long-term observation. Parasitol Res. 2012;110(6):2363-71.
Bass J, Mehta K, Glickman L, Blocker R, Eppes B. Asymptomatic toxocariasis in children. A prospective study and treatment trial. Clin Pediatr. 1987;26(9):441-6.
Cuellar C, Fenoy S, Aguila C, Guillen J. Evaluation of chemotherapy in experimental toxocarosis by determination of specific immune complexes. J Helminthol. 1990;64(4):279-89.
Elefant G, Shimizu S, Sanchez M, Jacob C, Ferreira A. A serological follow-up of toxocariasis patients after chemotherapy based on the detection of IgG, IgA, and IgE antibodies by enzyme-linked immunosorbent assay. J Clin Lab Anal. 2006;20(4):164-72.
O’Connell E, Nutman T. Eosinophilia in infectious diseases. Immunol Allergy Clin North Am. 2015;35(3):493-522.
Yoon S-Y, Baek S, Park SY, Shin B, Kwon H-S, Cho YS, et al. Clinical course and treatment outcomes of toxocariasis-related eosinophilic disorder. Medicine (Baltimore). 2018;97(37):e12361.
Nguyen T, Cheong F, Liew J, Lau Y. Seroprevalence of fascioliasis, toxocariasis, strongyloidiasis and cysticercosis in blood samples diagnosed in Medic Medical Center Laboratory, Ho Chi Minh City, Vietnam in 2012. Parasit Vectors. 2016;9(1):486.
Ain Tiewsoh J, Khurana S, Mewara A, Sehgal R, Singh A. Clinical and laboratory characteristics of patients with toxocariasis encountered at a tertiary care centre in North India. Indian J Med Microbiol. 2018;36(3):432-4.
Magnaval JF. Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis. Parasitology. 1995;110(5):529-33.
Glickman L, Magnaval J, Domanski L, Shofer F, Lauria S, Gottstein B, et al. Visceral larva migrans in French adults: a new disease syndrome? Am J Epidemiol. 1987;125(6):1019-34.
Wolfrom E, Cene G, Lejoly-Boisseau H, Beylot C. Urticaire chronique et Toxocara canis. Etude cas-temoin. Ann Dermatol Venereol. 1996;123:240-6.
Kim H-B, Seo J-W, Lee J-H, Choi B-S, Park S-G. Evaluation of the prevalence and clinical impact of toxocariasis in patients with eosinophilia of unknown origin. Korean J Intern Med. 2017;32(3):523-9.
Rubinsky-Elefant G, Hoshino-Shimizu S, Jacob C, Sanchez M, Ferreira A. Potential immunological markers for diagnosis and therapeutic assessment of toxocariasis. Rev Inst Med Trop Sao Paulo. 2011;53(2):61-5.
Altcheh J, Nallar M, Conca M, Biancardi M, Freilij H. Toxocariasis: aspectos clínicos y de laboratorio en 54 pacientes [Toxocariasis: clinical and laboratory features in 54 patients]. [Articale in Spanish]. An Pediatr. 2003;58(5):425-31.
Magnaval JF, Fabre R, Maurières P, Charlet JP, de Larrard B. Evaluation of an immunoenzymatic assay detecting specific anti-Toxocara immunoglobulin E for diagnosis and posttreatment follow-up of human toxocariasis. J Clin Microbiol. 1992;30(9):2269-74.
de Savigny D, Voller A, Woodruff A. Toxocariasis: serological diagnosis by enzyme immunoassay. J Clin Pathol. 1979;32(3):248-8.
Małafiej E, Spiewak E. The significance of the level of antibodies in the evaluation of the effects of treatment of toxocariasis. Wiad Parazytol. 2001;47(4):805-10.
Magnaval JF, Glickman LT, Dorchies P, Morassin B. Highlights of human toxocariasis. Korean J Parasitol. 2001;39(1):1-11.
Tiabendazole AJK. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions, 15th ed. Amsterdam Boston: Elsevier Science; 2006.
Moreira-Silva S, Rodrigues M, Pimenta J, Gomes C, Freire L, Pereira F. Toxocariasis of the central nervous system: with report of two cases. Rev Soc Bras Med Trop. 2004;37(2):169-74.